Panitumumab in RAS Wild-Type Left-Sided mCRC: Evidence Synthesis
This narrative review consolidates the biomarker-driven positioning of panitumumab and emerging combination strategies for oncology pharmacists managing metastatic colorectal cancer.
Panitumumab extends survival in metastatic colorectal cancer with precision therapy advances.
Metastatic colorectal cancer (mCRC) is a leading cause of cancer-related deaths, and targeted therapies like panitumumab offer potential improvements in treatment outcomes. Panitumumab extends overall survival by 5.6 months in first-line treatment. ctDNA analysis predicts treatment eligibility with a 30% response rate observed in rechallenge cases. Panitumumab shows significant efficacy in RAS wild-type mCRC, especially in left-sided tumors. Advances in molecular stratification and ctDNA monitoring can optimize its use. Panitumumab is vital for RAS wild-type mCRC treatment, with precision strategies enhancing its deployment.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Citation:Kwiatkowska L, Szczuko M The Role of Monoclonal Antibody Targeted Therapy (Panitumumab) in the Treatment of Metastatic Colorectal Cancer-A Narrative Review of Current Evidence and Emerging Therapeutic Strategies. International journal of molecular sciences. 2026;27(17). doi:10.3390/ijms27177559
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.